The global MicroRNA Market has entered a high growth phase, rising from a valuation of USD 1.3 billion in 2023 and projected to reach USD 7.7 billion by 2032. The market is set to advance at a CAGR of 21.1% from 2024 to 2032. This strong trajectory is supported by the rising adoption of miRNA tools in disease diagnosis, therapeutic development, precision medicine, and next generation research platforms. As clinical trials continue to expand for chronic and infectious diseases, miRNA technologies are becoming central to innovation in molecular biology and personalized care.
Growing interest in the regulatory functions of miRNAs has led scientists and healthcare organizations to integrate them into cancer profiling, viral diagnostics, and gene expression analysis. These applications have pushed biotechnology firms, academic institutes, and pharmaceutical developers to accelerate investments in miRNA workflows. The growing availability of advanced kits, reagents, profiling systems, and functional analysis tools is also contributing to market momentum.
Increasing use of miRNA signatures for cancer detection has become a major catalyst for revenue growth. In 2023, substantial investments in cancer research supported demand for miRNA diagnostics designed to classify cancer subtypes, detect early disease markers, and streamline targeted therapy strategies. In parallel, the market observed rising adoption of miRNA technologies in infectious disease studies, particularly after the pandemic amplified the need for sensitive and rapid molecular diagnostic tools.
Get free Sample Report@ https://www.snsinsider.com/sample-request/3143
In 2023, the services segment held the largest revenue share of 58.8 percent. This category includes isolation, purification, miRNA cDNA synthesis, profiling, localization, quantification, and functional analysis. The strong uptake of these services reflects the growing need for reliable and high precision research support. Innovations in target prediction and validation are enhancing accuracy and improving study outcomes. For instance, a study published in 2023 highlighted improved prediction accuracy for plant based miRNA targets through advanced modeling techniques. Such developments are helping researchers overcome barriers in genome based discovery and molecular classification.
The product segment is expected to register significant growth through 2032 as more companies introduce high quality consumables that include specialized kits, advanced reagents, and user friendly workflow tools. This direction is guided by rising demand for miRNA biomarkers in disease monitoring and diagnosis. Life sciences firms are focusing on product innovation to support sophisticated miRNA expression studies and to cater to the expanding research community.
Cancer remained the leading application segment in 2023 as researchers deepened their focus on understanding the role of miRNA signatures in tumor detection and disease staging. Clinical trials exploring miRNA based diagnostic tests and therapeutic options have added strength to the segment. Meanwhile, the infectious disease category is anticipated to report the highest CAGR over the forecast period. The segment gained strong traction during the pandemic as miRNA biomarkers played a valuable role in viral behavior studies and pathogen identification.
Biotechnology and pharmaceutical companies dominated the end user market in 2023. Ongoing collaborations with academic institutions have expanded access to advanced technologies and strengthened efforts in large scale research programs. New facilities and upgraded laboratories continue to push innovation in miRNA based detection tools. Academic and government research institutes are also expected to witness strong adoption rates as the number of research studies exploring miRNA mechanisms rapidly increases.
North America maintained the largest regional share in 2023 due to the strong presence of major industry players, including Thermo Fisher Scientific, Merck KGaA, NanoString Technologies, and QIAGEN. These organizations have accelerated R and D investment to introduce advanced miRNA solutions and support next generation molecular biology research. The United States accounted for the largest contribution within the region because of its well established distribution networks and robust innovation ecosystem.
Asia Pacific is projected to grow at the fastest pace from 2024 to 2032. Rising healthcare investment, rapid adoption of new technologies, and a strong pipeline of regional startups are key growth drivers. Countries such as China are witnessing increased support for omics research, combined with advancing precision medicine initiatives. Collaboration between traditional medical practices and modern scientific research is also influencing progress in miRNA technologies.
Leading market participants include Thermo Fisher Scientific, QIAGEN, NanoString Technologies, Merck KGaA, New England Biolabs, GeneCopoeia, Takara Bio, BioVendor, Miltenyi Biotec, SeqMatic, OriGene Technologies, and others. Recent developments highlight the strategic focus on expanding diagnostic platforms and strengthening molecular capabilities. For instance, Thermo Fisher announced a USD 3.1 billion investment in acquiring Olink Holding in 2023 to enhance its drug discovery portfolio. Similarly, QIAGEN launched upgraded digital PCR kits and advanced software tools to support broader applications in biopharma and food safety.
With continuous advancements in biomarker research, increasing adoption of molecular diagnostics, and a growing focus on precision healthcare, the MicroRNA Market is poised for substantial expansion through 2032.
Other Trending Reports
Personalized Cancer Vaccine Market
Compression Therapy Market Growth
Precision Diagnostics Market Growth
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Rohan Jadhav – Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
